A review written, in the authors' words, to inform the health sector recovery plan following recent political changes in Syria, that describes a centralised system with fragmented financing, heavy out-of-pocket payment, health insurance for under 5% of people and cancer medicines that patients largely paid for themselves.
Published as "The health system in Syria (2000-2024): assembling the pieces of a fragmented system: A scoping review". Following PRISMA-ScR guidelines and WHO's health system building blocks, the authors synthesised literature, grey literature and government reports. The full text states that before the conflict Syria's pharmaceutical industry covered 90% of domestic medicine needs from more than 70 factories, that the Ministry of Health approved new medicines, monitored quality and set price controls, that higher-cost treatments such as cancer drugs required direct payment, that out-of-pocket spending was about 61% of health spending by 2008, and that small fragmented insurance schemes covered less than 5% of the population by the end of 2020.
Explains why a Syrian with cancer has often paid for medicines out of pocket even where hospital care is free.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/